Significant correlations with immunochemical staining was also obtained for the 48 DLBCL samples from the RT3 clinical trial (CD10, BCL6, MUM1, MYC, BCL2, and Ki67, reviewed by a panel of expert pathologists from the LYSA) (Supplemental Fig. 2), indicating excellent technical concordances. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.